Magazines and books

Publications and Presentations

Published data and presentations from medical conferences for Karyopharm’s investigational drug candidates

This page is intended to provide scientific information to scientific research professionals. XPOVIO (selinexor) has only been approved by the United States Food and Drug Administration (FDA) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Karyopharm’s other drug candidates, including selinexor in additional indications, are investigational medicines and have not been approved by FDA, Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.  

Featured Research

Multiple Myeloma


Diffuse Large B-cell Lymphoma (DLBCL)


Other Hematologic Malignancies


Solid Tumors